Kristi Dodbiba, DO
Nephrology · Bryn Mawr, PANPI 1902362437
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 87 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,376, more than ten times the $122 reported in 2019.
Across 87 payments — averaging $26.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$509
- Bayer$306
- Lilly USA, LLC$290
- Novartis$165
- Calliditas Therapeutics US Inc.$157
- Otsuka America Pharmaceutical, Inc.$113
- plus $726 from 13 others
What the payments were for
- Food & beverage$2,21998%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $509 |
| Bayer | 18 | $306 |
| Lilly USA, LLC | 11 | $290 |
| Novartis | 6 | $165 |
| Calliditas Therapeutics US Inc. | 5 | $157 |
| Otsuka America Pharmaceutical, Inc. | 4 | $113 |
| Amgen | 4 | $108 |
| Vifor Pharma, Inc. | 5 | $104 |
| Ardelyx, Inc. | 4 | $88 |
| Scpharmaceuticals Inc. | 2 | $88 |
| Novo Nordisk | 3 | $74 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $57 |
| Travere Therapeutics, Inc. | 2 | $49 |
| OPKO Pharmaceuticals, LLC | 2 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| AbbVie | 1 | $24 |
| Fresenius USA Marketing, Inc. | 1 | $23 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| Nxstage Medical, Inc. | 1 | $19 |
How this compares
$2,266 in reported general payments places this provider in the 75th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Losartan Potassium | 11 | $101 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Bryn Mawr
- Anthony KentBryn Mawr$58K
- Sophia MoldavskyBryn Mawr$7K
- Nelson KopytAllentown$949K
- Christopher GislerPittsburgh$757K
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Prince AnandDanville$331K
- Ellie KelepourisPhiladelphia$287K
- Jonathan DiamondHarrisburg$249K
- Abdallahsassine GearaPhiladelphia$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.